Cosentyx, also known as secukinumab, is a medication used to treat several conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The standard dosing schedule for Cosentyx can vary depending on the specific condition it is being used to treat.

For the treatment of plaque psoriasis, the recommended dosing schedule is 300 mg (as two 150 mg injections) at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks [1].

For the treatment of psoriatic arthritis, the recommended dosing schedule is 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks [1].

For the treatment of ankylosing spondylitis, the recommended dosing schedule is 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks [1].

It is important to note that the dosing schedule may be adjusted based on the patient's response to treatment and individual needs. Additionally, Cosentyx should be administered by a healthcare professional and should not be self-injected [1].

It is also important to be aware of the potential side effects of Cosentyx, which can include upper respiratory infections, headache, and injection site reactions [1].

In summary, the standard dosing schedule for Cosentyx is 300 mg (as two 150 mg injections) at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks for the treatment of plaque psoriasis, and 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks for the treatment of psoriatic arthritis and ankylosing spondylitis. However, the dosing schedule may be adjusted based on individual needs and the patient's response to treatment.

Sources:

[1] <https://www.drugs.com/cosentyx.html>
[2] <https://www.drugpatentwatch.com/drugs/cosentyx>